Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cedryl Acetate SCHEMBL17409526 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL18138231 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL27084023 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL17627733 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL18604009 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL1532502 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL8515562 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL30392817 | 1.00 | ALOX15 (1.00) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| SCHEMBL8736276 | 0.86 | ALOX15 (0.75) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA | |
| Cedryl Acetate SCHEMBL22498452 | 0.85 | ALOX15 (0.72) | ALOX15CYP17A1CYP19A1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481592-B2 | Uses of sesquiterpene derivatives | KWANG DONG PHARM CO., LTD. (KR) | 2013-07-09 | — | — | US | disclosed |
| US-20120129924-A1 | USES OF SESQUITERPENE DERIVATIVES | KWANG DONG PHARM. CO., LTD. (KR) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129924-A1 | USES OF SESQUITERPENE DERIVATIVES | LIPC, PNLIP, FABP1 | ALOX15 120/4885CYP17A1 45/4885CYP19A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.